摘要
目的对比罗沙司他与重组人促红细胞生成素(rHuEPO)对维持性血液透析(MHD)患者冠状动脉钙化的影响。方法采用回顾性分析的方法,选取重庆医科大学附属第一医院血液净化中心2019年4月至2021年6月处方中含罗沙司他的56例MHD患者作为ROX组,同期处方中含rHuEPO的60例MHD患者作为EPO组,随访观察12个月,比较两组患者治疗前后实验室检查指标、冠状动脉钙化积分(CACS)、心脏超声参数的差异及随访期间心脑血管事件发生情况。结果治疗前及治疗后两组患者的CACS比较,差异均无统计学意义(P>0.05);但ROX组患者治疗前后的CACS差值明显低于EPO组患者(P<0.05)。两组患者治疗前后心脏超声参数及实验室检查指标比较,差异均无统计学意义(P>0.05)。随访期间,ROX组患者的脑卒中和心肌梗死发生率显著低于EPO组(P<0.05),但两组间因心衰住院的发生率差异无统计学意义(P>0.05)。结论与rHuEPO比较,罗沙司他可能对延缓MHD患者冠状动脉钙化有积极作用,且可能有利于减少MHD患者心肌梗死、脑卒中的发生。
OBJECTIVE To compare the effects of roxadustat and recombination human erythropoietin(rHuEPO)on coronary artery calcification in maintenance hemodialysis(MHD)patients.METHODS In retrospective analysis,MHD patients prescribed roxadustat in the Blood Purification Center of the First Affiliated Hospital of Chongqing Medical University from April 2019 to June 2021 were selected as the ROX group(56 patients),and MHD patients prescribed rHuEPO during the same period were selected as the EPO group(60 patients),and follow-up observation was conducted for 12 months.The differences in laboratory index,coronary artery calcification score(CACS),and cardiac ultrasound parameters before and after treatment as well as the occurrence of cardiac and cerebrovascular adverse events during follow-up period were compared between the two groups.RESULTS There was no statistical difference in CACS between the two groups before and after treatment(P>0.05);but the difference of CACS in the ROX group was significantly lower than the EPO group(P<0.05).There was no statistically significant difference in cardiac ultrasound parameters and laboratory indexes between the two groups before and after treatment(P<0.05).The incidence of apoplexy and myocardial infarction in the ROX group was lower than that in the EPO group(P<0.05),and there was no statistically significant difference in the incidence of hospitalization due to heart failure between the two groups(P>0.05).CONCLUSIONS Compared with rHuEPO,roxadustat may have a positive effect on delaying coronary artery calcification in MHD patients and may be beneficial in reducing the incidence of myocardial infarction and apoplexy in MHD patients.
作者
文杨
夏运风
甘华
李正荣
龚颖
WEN Yang;XIA Yunfeng;GAN Hua;LI Zhengrong;GONG Ying(Dept.of Nephrology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处
《中国药房》
CAS
2024年第5期590-594,共5页
China Pharmacy
基金
重庆市卫生健康委医学科研项目(No.2022-WSJK012)。
关键词
罗沙司他
重组人促红细胞生成素
维持性血液透析
冠状动脉钙化
roxadustat
recombination human erythropoietin
maintenance hemodialysis
coronary artery calcification
